Doses and schedules of rapamycin for longevity: does aging exist or only age-related diseases?

Doses and schedules of rapamycin for longevity: does aging exist or only age-related diseases?    Mikhail Blagosklonny This is a brief version of “groundbreaking paper” that I have no time to finish.   Rapamycin for life-limiting disease/condition Current doses and schedules of rapamycin for longevity are based on the wrong objective: to minimize side effects. … Continue Reading

Cancer prevention with rapamycin

      Cancer prevention with rapamycin   Mikhail V. Blagosklonny   Introduction The mTOR (Target of Rapamycin) pathway is involved in both cancer and aging. Furthermore, common cancers are age-related diseases, and their incidence increases exponentially with age. In theory, rapamycin (sirolimus) and other rapalogs (temsirolimus, everolimus) may delay cancer by targeting directly pre-cancerous … Continue Reading

Rapamycin for COVID-19 by Mikhail V. Blagosklonny

Section 11 from forthcoming review entitled “From causes of aging to death from COVID-19” (read full review soon) As soon as COVID-19 epidemic started, it become clear that COVID-19 vulnerability is aging-dependent condition and the use of rapamycin (Sirolimus) was immediately suggested by independent researches {Sargiacomo, 2020 #9}, {Zhavoronkov, 2020 #105}, {Zhou, 2020 #94}{Omarjee, 2020 … Continue Reading

How rapamycin prevents muscle loss and sarcopenia (first draft)

The effect of rapamycin, an anti-aging drug, on the muscle, was puzzling for a decade. It seemed paradoxical that rapamycin, an inhibitor of mTOR component 1 (mTORC1), prevents muscle loss and sarcopenia. Yet, this is well established [1-5]. How is that possibly possible?  The nutrient-sensing mTOR pathway increases protein synthesis and cellular mass growth. Furthermore, … Continue Reading

Rapamycin: time is now … unless it’s too late

In 2006, I published an article that aging is not caused by free radicals nor by any kind of molecule damage but instead is a quasi-program driven in part by mTOR (Target of Rapamycin). By sheer luck, mTOR inhibitors – Sirolimus (rapamycin) and Everolimus – were clinically available. As I summarized in 2006: “…all diseases of aging … Continue Reading